patent.fyi
Applications  /  US 2026/0356842
United States Patent Application Publication

US 2026/0356842 A1

Published
Nov 12, 2026
Filed
Jul 8, 2026
Earliest date on the face
Feb 21, 2020
Classification
C07D 487/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Fluorinated aromatic ring position

What ifWhat if Q1 is an aromatic carbon bonded to fluorine and Q2 is N?
Claim language“independently N or CH”

The carbon at Q1 retains its two ring bonds and forms an exocyclic C–F bond. Q2 supplies an aromatic nitrogen acceptor while the C–F bond changes the local electron distribution.

1.3Sulfur at the bridge

What ifWhat if Q3 is a divalent sulfur atom?
Claim language“CH2 or NH”

The sulfur forms two single bonds to the atoms flanking Q3 and closes the ring at the same position. The longer bonds at sulfur change the local ring geometry.

1.4Sulfone at the linker

What ifWhat if Z is a sulfonyl group, —S(═O)2—?
Claim language“CR11aR11b, NR12, or O”

Sulfur forms a single bond to each atom flanking Z and carries two sulfonyl oxygens. The group connects the same attachment points and supplies two hydrogen-bond acceptors.

1.6Hydroxyethyl on the linker nitrogen

What ifWhat if R12 is 2-hydroxyethyl?
Claim language“hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, or —(C1-C4 alkyl)(C3-C6 cycloalkyl)”

The nitrogen at Z bonds to the first carbon of an —CH2CH2OH chain and retains its two scaffold bonds. The terminal hydroxyl supplies a hydrogen-bond donor and acceptor two carbons from nitrogen.

1.7Methylsulfonyl at a ring position

What ifWhat if R1a is methylsulfonyl?
Claim language“C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino”

The scaffold bonds directly to the sulfur of an —S(═O)2CH3 group. The two sulfonyl oxygens supply hydrogen-bond acceptors, and the group withdraws electron density from the attachment site.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Carbonyl at the ring bridge

A carbonyl group replaces the methylene at Z while keeping the same two ring attachments. The carbonyl carbon occupies the Z position, and the oxygen projects from the ring. The carbonyl oxygen acts as a hydrogen-bond acceptor and introduces a local dipole at the bridge.

Parameter or scale variation

Three lengths for the carbon linker

A matched series connects the scaffold to a cyclohexyl ring through a carbon linker at R2. The series uses zero, one, or two methylene units, giving direct cyclohexyl, cyclohexylmethyl, and cyclohexylethyl attachments. All other scaffold positions stay fixed so that the series varies the attachment distance and the number of rotatable bonds.

Combination with existing systems

Adenine analogs in a mitochondrial reporter assay

A multiwell cell assay combines the adenine analogs with a mitochondria-targeted fluorescent reporter that changes its emission ratio when mitochondria reach acidic compartments. Each plate contains compound-treated wells, solvent controls, and cells lacking PINK1. A plate reader measures both emission channels, and the assay compares their ratio across the matched cell groups.

Permeability measurement across an artificial membrane

A parallel artificial membrane permeability assay places a lipid-coated porous filter between donor and receiver wells. The donor wells contain dissolved adenine analogs, and the receiver wells contain buffer. Liquid chromatography measures compound concentrations on both sides after incubation, and the receiver concentration provides the transferred amount used to estimate apparent permeability.

Automated or data-driven variant

Software selection of matched analog pairs

Molecular graph software stores the scaffold with atom labels at each variable position and generates candidate structures by changing one position at a time. The software checks atom valences and removes duplicate structures using canonical molecular graph identifiers. It exports compound pairs and assigns each pair to adjacent wells for side-by-side measurement.

Specific version of a part

Carbonyl at the linker

Z contains a carbonyl carbon with a double bond to oxygen and single bonds to the two flanking atoms. The carbonyl oxygen serves as a hydrogen-bond acceptor.

Two methylenes after oxygen

The —O(CH2)nCy1 arrangement uses n = 2 and cyclohexyl as Cy1. The spacer connects the ether oxygen to a cyclohexyl ring carbon through two consecutive methylene groups.

Methyl on the linker nitrogen

R13 is methyl in an —N(CH3)CH2Cy1 side chain with n = 1. The linker nitrogen bonds to the scaffold, the methyl carbon, and the methylene carbon leading to Cy1.

Cyanopyridyl end group

Cy1 is a 5-cyanopyridin-3-yl group. The pyridine ring attaches through carbon 3 and carries one cyano substituent at carbon 5.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0099236 A1
Published
Apr 16, 2009
Filed
Oct 8, 2008
Class
A61K 31/4439
Document BUS 2011/0098468 A1
Published
Apr 28, 2011
Filed
Dec 14, 2010
Class
C07D 207/14
Claim 1
Document A
Document B
1.1m is 0 or 1
1.2wherein each of Q1 and Q2 is independently N or CH
1.3wherein Q3 is CH2 or NH
1.4wherein Z is CR11aR11b, NR12, or O
when X1 is —O—, —S— or —NR34—, then: R1 and R2 are each independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C3alkyl), C3-C8 cycloalkyl, —CH2F, —CHF2 and —CF3; or R1 and R2, together with the carbon atom to which they are both attached, form a chemically feasible C3 to C6 alkylene ring; or R1 and R2, together with one another and the carbon atom to which they are both attached, form a C═O group;
B · US 2011/0098468 A1 · ¶ 13
1.5wherein each of R11a and R11b, when present, is independently selected from hydrogen, halogen, —OH, and C1-C4 alkyloxy, or wherein each of R11a and R11b, when present, together comprise ═O
Rc and Rd each independently is: hydrogen; or alkyl; or Rc and Rd together form ═O, ═S, or ═NRf, wherein Rf is hydrogen, alkyl, or —ORg, wherein Rg is hydrogen or alkyl; or one of R2 and R3 together with one of Rc and Rd together with the atoms to which they are attached may form a four to six membered ring that optionally includes an additional heteroatom selected from O, N and S; and Re is hydrogen or alkyl.
A · US 2009/0099236 A1 · claim 28
1.6wherein R12, when present, is hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, or —(C1-C4 alkyl)(C3-C6 cycloalkyl)
Rb and Rc are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and when n is 0, Rd is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, Rd is alkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino.
A · US 2009/0099236 A1 · ¶ 87
1.7wherein each of R1a, R1b, R1c, and R1d is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino
R1 is phenyl, pyridinyl, or indolyl each of which is optionally substituted with one, two, three or four substituents each of which is independently selected from alkyl, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkoxyalkyl or hydroxyalkyl; and one of R2 and R3 is hydrogen while the other is alkyl, preferably methyl.
A · US 2009/0099236 A1 · ¶ 244
each R19 is a substituent on the aryl or heteroaryl ring to which it is attached, and is independently selected from the group consisting of H, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, —OH, halogen, —CN, —NO2, —CF3, —CHF2, —CH2F, —OCF3, —OCHF2, —OCH2F, —O—(C1-C6 alkyl), —O—(C3-C8 cycloalkyl), —COOR12, —CONR21R22, —OC(O)NR21R22, —OC(O)R12, —NR21R22, —NR21COR12, —NR21CO2R12, —NR21CONR21R22, —NR21SO2R15 and —S(O)n6R15;
B · US 2011/0098468 A1 · ¶ 34
1.8wherein R2 is selected from —(CH2)nCy1, —O(CH2)nCy1, —NR13(CH2)nCy1, —CH(OH)Cy1, and Cy1
1.9wherein n, when present, is 0, 1, or 2
1.10wherein R13, when present, is selected from hydrogen and C1-C4 alkyl
Ar is indolyl optionally substituted with one, two, three or four substituents each independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, alkylsulfonyloxy, —(CH2)q—S(O)rRf; —(CH2)q—NRgRh; or —(CH2)q—C(═O)—NRgRh; where q is 0 or 1, r is from 0 to 2, and each of Rf, Rg, and Rh is independently hydrogen or alkyl;
A · US 2009/0099236 A1 · ¶ 244
1.11wherein Cy1 is a C4-C9 cycloalkyl, a C3-C9 heterocycle having at least one O, S, or N atom, or a C2-C9 heteroaryl having at least one O, S, or N atom, and substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, ═O, C3-C6 cycloalkyl, C2-C5 heterocycloalkyl, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, —(C1-C4)-O—(C1-C4 alkyl), —C(O)(C1-C4 alkyl), —S(O)R14, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino
Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated derivatives thereof.
A · US 2009/0099236 A1 · ¶ 83
where, n1 is 0 to 5; and G is H, —CF3, —CHF2, —CH2F, —OH, —O—(C1-C6 alkyl), —OCH2F, —OCHF2, —OCF3, —OCH2CF3, —O—(C3-C8 cycloalkyl), —O—(C1-C6)alkyl(C3-C8 cycloalkyl), —NR13R14, —SO2NR13R14, —NR12SO2R13, —NR12C(O)R14, —NR12C(O)OR13, —NR12(C(O)NR13R14), —C(O)NR13R14, —C(O)OR13, —C3-C8 cycloalkyl, (R19)r-aryl, (R19)r-heteroaryl, —OC(O)R14, —OC(O)NR13R14, —C(═NOR14)(R13), —C(O)R13, —C(OR12)(R13)(R14), heterocycloalkenyl optionally substituted by 1 to 4 substituents independently
B · US 2011/0098468 A1 · ¶ 20
1.12wherein R14, when present, is selected from —OH, —NH2, —O(C1-C4 alkyl), —NH(C1-C4 alkyl), and —N(C1-C4 alkyl)(C1-C4 alkyl) wherein R3 is a 3- to 6-membered cycloalkyl, a C1-C6 haloalkyl, C1-C6 haloalkoxy, or C1-C6 halohydroxyalkyl wherein R4 is selected from hydrogen and C1-C4 alkyl, or a pharmaceutically acceptable salt thereof.
R1 and R2 are independently selected from the group consisting of H, C1-C6 alkyl or hydroxyl (C1-C3alkyl), C3-C8 cycloalkyl; —CH2F, CHF2, —CF3, R3 is H, C1-C5alkyl, hydroxyC1-C3alkyl, C3-C8cycloalkyl, CH2F, CF2H or CF3;
B · US 2011/0098468 A1 · claim 41

An empty cell means only that no passage was reproduced there.

Statements in these documents
In particular, compounds of the present invention are useful for treatment of diseases associated with monoamine reuptake inhibitors.
A · US 2009/0099236 A1 · ¶ 2
Dual reuptake inhibitors of serotonin and norepinephrine also offer potential treatments for disorders and disease states of the urinary tract, and for pain and inflammation.
A · US 2009/0099236 A1 · ¶ 4
It would be beneficial to provide a NK1 antagonist that is potent, selective, and possesses beneficial therapeutic and pharmacological properties, and good metabolic stability.
B · US 2011/0098468 A1 · ¶ 6
It would further be beneficial to provide a NK1 antagonist that is effective for treating a variety of physiological disorders, symptoms and diseases while minimizing side effects.
B · US 2011/0098468 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0356842 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356842/, SHA-256 25db7f6f49ca86bc7f2c772bd5eb54163ebcb27f0c88d46db2595443d5328d3f
First published
Permanent addresshttps://patent.fyi/US20260356842/
Content fingerprint (SHA-256)25db7f6f49ca86bc7f2c772bd5eb54163ebcb27f0c88d46db2595443d5328d3f
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi